/term/ShortPercentageOfFloat/FRA:MOL Moleculin Biotech (FRA:MOL) Short Percentage of Float
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Short Percentage of Float

Moleculin Biotech (FRA:MOL) Short Percentage of Float


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Moleculin Biotech's Short Percentage of Float

For the Biotechnology subindustry, Moleculin Biotech's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moleculin Biotech's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Short Percentage of Float falls into.


Moleculin Biotech (FRA:MOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Short Percentage of Float
Comparable Companies
FWPAY APRE TARA ONTX OCEL CALC GOVX VBIV SNSE MLCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MBRX:USA 0K2H:UK
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Website
https://www.moleculin.com
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.

Moleculin Biotech (FRA:MOL) Headlines

No Headlines